Novo Nordisk, the Danish pharma company behind Ozempic, made a very dumb decision a few years ago that will massively eat ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to advance at a resilient ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

Drugmakers want more clarity from the Trump administration on the potential pharmaceutical tariffs, which some companies warn ...

Improving drug access and affordability is a key health care policy issue with strong bipartisan support, health care experts ...

Generic Drugs Market Size to Reach USD 769.52 Billion by 2033 | Says Cervicorn ConsultingThe generic drugs market size is ...

I’m sure someone’s lost their job,” said the CEO of Sandoz, which has now filed to launch a generic GLP-1 drug in Canada next ...

In this video, Peter K. Kaiser, MD, founding director of the Digital Eye Optical Coherence Tomography Reading Center at the Cole Eye Institute, discusses navigating the treatment landscape for wet age ...

In this video, Peter K. Kaiser, MD, founding director of the Digital Eye Optical Coherence Tomography Reading Center at the Cole Eye Institute, discusses disparities in wet age-related macular ...

Novo Nordisk (NYSE: NVO) has permanently forfeited Canadian patent protection for semaglutide—the blockbuster active ...